SANTA CRUZ BIOTECHNOLOGY, INC.

DARPP-32 (H-62): sc-11365



BACKGROUND

Dopaminergic signaling pathways, which are essential for multiple brain functions, are abnormal in several neurological disorders, such as schizophrenia, Parkinson's disease and drug abuse. DARPP-32 (for dopamine and adenosine 3',5'-monophosphate-regulated phosphoprotein) is abundant in neurons that receive dopaminergic input. Activation of PKA and the consequent phosphorylation of DARPP-32 on threonine occurs in response to dopamine acting upon D1-like receptors. Dopamine interaction with D2-like receptors results in the inhibition of PKA activation, the activation of protein phosphatase 2B and the consequent dephosphorylation of DARPP-32. Neurotransmitters other than dopamine may also be able to stimulate the phosphorylation or dephosphorylation of DARPP-32. Phosphorylated DARPP-32 is a potent inhibitor of PP-1.

CHROMOSOMAL LOCATION

Genetic locus: PPP1R1B (human) mapping to 17q12; Ppp1r1b (mouse) mapping to 11 D.

SOURCE

DARPP-32 (H-62) is a rabbit polyclonal antibody raised against amino acids 134-195 mapping epitope corresponding to amino acids 134-195 of DARPP-32 of bovine origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Available as agarose conjugate for immunoprecipitation, sc-11365 AC, 500 $\mu g/0.25$ ml agarose in 1 ml.

APPLICATIONS

DARPP-32 (H-62) is recommended for detection of DARPP-32 of human, bovine and, to a lesser extent, mouse and rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for DARPP-32 siRNA (h): sc-35173, DARPP-32 siRNA (m): sc-35174, DARPP-32 siRNA (r): sc-156003, DARPP-32 shRNA Plasmid (h): sc-35173-SH, DARPP-32 shRNA Plasmid (m): sc-35174-SH, DARPP-32 shRNA Plasmid (r): sc-156003-SH, DARPP-32 shRNA (h) Lentiviral Particles: sc-35173-V, DARPP-32 shRNA (m) Lentiviral Particles: sc-35174-V and DARPP-32 shRNA (r) Lentiviral Particles: sc-156003-V.

Molecular Weight of DARPP-32: 32 kDa.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA





DARPP-32 (H-62): sc-11365. Western blot analysis of rat recombinant DARPP-32.

DARPP-32 (H-62): sc-11365. Immunofluorescence staining of methanol-fixed SK-N-SH cells showing cytoplasmic localization (**A**). Immunoperoxidase staining of formalin fixed, paraffin-embedded human brain tumor showing cytoplasmic localization (**B**).

SELECT PRODUCT CITATONS

- 1. El-Rifai, W., et al. 2002. Gastric cancers overexpress DARPP-32 and a novel isoform, τ -DARPP. Cancer Res. 62: 4061-4064.
- Kondo, Y., et al. 2010. Expression and role of the BDNF receptor-TrkB in rat adrenal gland under acute immobilization stress. Acta Histochem. Cytochem. 43: 139-147.
- Mukherjee, K., et al. 2010. Dopamine and cAMP regulated phosphoprotein MW 32 kDa is overexpressed in early stages of gastric tumorigenesis. Surgery 148: 354-363.
- Alvaro-Bartolome, M., et al. 2011. Molecular adaptations of apoptotic pathways and signaling partners in the cerebral cortex of human cocaine addicts and cocaine-treated rats. Neuroscience 196: 1-15.
- Dong, G., et al. 2011. Modeling pathogenesis of Huntington's disease with inducible neuroprogenitor cells. Cell. Mol. Neurobiol. 31: 737-747.
- Zhu, S., et al. 2011. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Gastroenterology 141: 1738-1748.e1-2.
- Chien, C.C., et al. 2012. Naloxonazine, a specific μ-opioid receptor antagonist, attenuates the increment of locomotor activity induced by acute methamphetamine in mice. Toxicol. Lett. 212: 61-65.
- 8. Hong, J., et al. 2012. Regulation of ERBB2 receptor by τ -DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma. Cancer Res. 72: 4504-4514.
- 9. Pauly, M.C., et al. 2013. Organization of the human fetal subpallium. Fronti. Neuroanat. 7: 54.



Try DARPP-32 (H-3): sc-271111 or DARPP-32 (G-5): sc-398360, our highly recommended monoclonal aternatives to DARPP-32 (H-62). Also, for AC, HRP, FITC, PE, Alexa Fluor[®] 488 and Alexa Fluor[®] 647 conjugates, see DARPP-32 (H-3): sc-271111.